Երկիր: Իսրայել
Լեզու: անգլերեն
Աղբյուրը: Ministry of Health
ATENOLOL
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
C07AB03
TABLETS
ATENOLOL 100 MG
PER OS
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
ATENOLOL
ATENOLOL
Management of angina pectoris and hypertension,including hypertension of renal origin. Late intervention after acute myocardial infarction.
2010-04-30
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed with a doctor’s prescription only NORMITEN ® 25 MG TABLETS COMPOSITION Each tablet contains atenolol as follows: Atenolol 25 mg NORMITEN ® 50 MG TABLETS COMPOSITION Each tablet contains atenolol as follows: Atenolol 50 mg NORMITEN ® 100 MG TABLETS COMPOSITION Each tablet contains atenolol as follows: Atenolol 100 mg For the list of inactive ingredients in the preparation, see section 6 – “Further Information”. READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. THIS MEDICINE HAS BEEN PRESCRIBED FOR THE TREATMENT OF YOUR AILMENT. DO NOT PASS IT ON TO OTHERS. IT MAY HARM THEM EVEN IF IT SEEMS TO YOU THAT THEIR MEDICAL CONDITION IS SIMILAR. THIS MEDICINE IS NOT INTENDED FOR USE IN CHILDREN. 1. WHAT IS THE MEDICINE INTENDED FOR? A preparation from the beta-adrenergic receptor blocker group (beta blockers), for the treatment of angina pectoris, acute myocardial infarction (after a heart attack) and hypertension. THERAPEUTIC GROUP Selective beta 1 receptor blocker. 2. BEFORE USING THE MEDICINE DO NOT USE NORMITEN IF: ∙ you are sensitive (allergic) to atenolol or any of the other ingredients of the medicine (see section 6). ∙ you have suffered in the past from heart problems, especially uncontrollable heart failure (which usually causes shortness of breath and swelling of the ankles), second- or third-degree heart block (a condition which can be treated by a pacemaker), very slow or irregular heart beats/rate, very low blood pressure or severe disturbances in blood circulation. ∙ you are suffering from cardiogenic shock, manifested by a significant reduction in blood pressure, pallor, restlessness, fast and weak heartbeat, clammy skin, stupor. ∙ you have low blood pressure. ∙ you are being treated with intravenous verapamil or diltiazem Կարդացեք ամբողջական փաստաթուղթը
This leaflet format has been determined by the Ministry of Health and the content thereof has been checked approved on March 2016 1. Name of the medicinal product Normiten 25, 50, 100 2. Qualitative and quantitative composition Atenolol 25, 50, 100 mg. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Tablets. 4. Clinical particulars 4.1 Therapeutic indications Normiten is indicated in the treatment of: • Hypertension. • Angina pectoris. • Myocardial infarction. 4.2 Posology and method of administration Posology The dose must always be adjusted to individual requirements of the patients, with the lowest possible starting dosage. The following are guidelines: Adults _Hypertension _ Initially 25-50 mg once a day, the dosage being increased gradually to 100 mg a day after two weeks, as needed and tolerated. _ _ _Angina _ Initially 50 mg once a day, the dosage being increased gradually to 100 mg after 1 week, as needed and tolerated. _Myocardial infarction _ _ _ For patients who present some days after suffering an acute myocardial infarction, an oral dose of Normiten 100 mg daily is recommended for long-term prophylaxis of myocardial infarction . Older population Dosage requirements may be reduced, especially in patients with impaired renal function. Paediatric population There is no paediatric experience with Atenolol and for this reason Normiten is not recommended for use in children. Renal failure Since Atenolol is excreted via the kidneys, the dosage should be adjusted in cases of severe impairment of renal function. No significant accumulation of Atenolol occurs in patients who have a creatinine clearance greater than 35 ml/min/1.73 m 2 (normal range is 100–150 ml/min/1.73 m 2 ). For patients with a creatinine clearance of 15–35 ml/min/1.73 m 2 (equivalent to serum creatinine of 300–600 micromol/litre), the oral dose should be 50 mg daily. For patients with a creatinine clearance of less than 15 ml/min/1.73 m 2 (equivalent to serum creatinine of greater than 600 micromol/litre Կարդացեք ամբողջական փաստաթուղթը